Home -> Law Blog Directory -> Personal Injury Law Blogs -> Philadelphia Personal Injury Lawyer
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Personal Injury Law
: Philadelphia Personal Injury LawyerBleeding Problems With Xigris
By Jamie Sheller
Xigris, a drug made by Eli Lilly, has drawn the scruting of federal regulators. The FDA is looking at Xigris, which is used to treat severe sepsis or blood infections, to determine a possible risk that the drug may cause serious bleeding. According to the FDA, a retrospective study of 73 patients who used Xigris, showed an increased risk of serious bleeding and death. A description of the risk of bleeding is already on the drug's label. The retrospective study that drew the FDA's attention was published in the journal Critical Care Medicine, and an accompanying editorial indicated that doctors should not give Xigris to sepsis patients who already have an increased risk for bleeding problems.
Studies, like the one published in Critical Care Medicine, can help uncover patterns of side effects and increased risks that come with prescription medications. It is important for the FDA to follow-up with such studies to determine the risk to the public. The FDA can then take appropriate steps with respect to the medication, such as label changes or recalls.
Originally posted at InjuryBoard by Jamie ShellerFull post as published by Philadelphia Personal Injury Lawyer on February 05, 2009 (boomark / email).
Xigris
Study Prompts FDA Safety Review
FenPhen
Serious Heart Problems Found In Ex-Users
Food Dyes Linked to Behavioral Problems
Ban Urged
Healon D
Reports of Postoperative Eye Problems Prompts FDA Recall
Toxic Mold
exposure allegedly can lead to serious health problems.
Unapproved Drugs
Causing Vision Loss and Blood Pressure Problems

2008 Bringing on More Trasylol Lawsuits
FDA Recall of PHENYLPROPANOLAMINE
Serious Risk Of Bleeding When Heparin Is Administered Shortly After Stroke







